Literature DB >> 29925508

TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus.

Kongyang Ma1, Jingyi Li2, Xiaohui Wang1, Xiang Lin1, Wenhan Du1, Xi Yang1, Fangxiang Mou2, Yongfei Fang2, Yanbin Zhao3, Xiaoping Hong3, Kwok Wah Chan1, Xiaoming Zhang4, Dongzhou Liu3, Lingyun Sun5, Liwei Lu1.   

Abstract

OBJECTIVES: In patients with systemic lupus erythematosus (SLE), immune tolerance breakdown leads to autoantibody production and immune-complex glomerulonephritis. This study aimed to identify pathogenic plasma cells (PC) in the development of lupus nephritis.
METHODS: PC subsets in peripheral blood and renal tissue of patients with SLE and lupus mice were examined by flow cytometry and confocal microscopy, respectively. Sorting-purified PCs from lupus mice were adoptively transferred into Rag2-deficient recipients, in which immune-complex deposition and renal pathology were investigated. In culture, PCs from lupus mice and patients with SLE were treated with a TLR4 inhibitor and examined for autoantibody secretion by enzyme-linked immunospot assay (ELISPOT). Moreover, lupus mice were treated with a TLR4 inhibitor, followed by the assessment of serum autoantibody levels and glomerulonephritis activity.
RESULTS: The frequencies of TLR4+CXCR4+ PCs in peripheral blood and renal tissue were found significantly increased with the potent production of anti-dsDNA IgG, which were associated with severe renal damages in patients with SLE and mice with experimental lupus. Adoptive transfer of TLR4+CXCR4+ PCs from lupus mice led to autoantibody production and glomerulonephritis development in Rag2-deficient recipients. In culture, TLR4+CXCR4+ PCs from both lupus mice and patients with SLE showed markedly reduced anti-dsDNA IgG secretion on TLR4 blockade. Moreover, in vivo treatment with TLR4 inhibitor significantly attenuated autoantibody production and renal damages in lupus mice.
CONCLUSIONS: These findings demonstrate a pathogenic role of TLR4+CXCR4+ PCs in the development of lupus nephritis and may provide new therapeutic strategies for the treatment of SLE. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  B cells; autoantibodies; autoimmune diseases; lupus nephritis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 29925508     DOI: 10.1136/annrheumdis-2018-213615

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  CXCR4 and CXCR5 orchestrate dynamic germinal center reactions and may contribute to the pathogenesis of systemic lupus erythematosus.

Authors:  Bing-Xuan Wu; Li-Dan Zhao; Xuan Zhang
Journal:  Cell Mol Immunol       Date:  2019-06-03       Impact factor: 11.530

2.  A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A.

Authors:  M Pérez-Ferro; F I Romero-Bueno; C Serrano Del Castillo; I Mahillo; A Alvear; R Largo; G Herrero-Beaumont; O Sánchez-Pernaute
Journal:  Clin Exp Immunol       Date:  2019-02-27       Impact factor: 4.330

3.  Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis.

Authors:  Yuye Yin; Xinyi Yang; Shusheng Wu; Xinyu Ding; Huamin Zhu; Xuehui Long; Yuliang Wang; Sulan Zhai; Yun Chen; Nan Che; Jingjing Chen; Xiaoming Wang
Journal:  Nat Immunol       Date:  2022-08-22       Impact factor: 31.250

Review 4.  Epigenetic regulation of B cells and its role in autoimmune pathogenesis.

Authors:  Fan Xiao; Ke Rui; Xiaofei Shi; Haijing Wu; Xiaoyan Cai; Kathy O Lui; Qianjin Lu; Esteban Ballestar; Jie Tian; Hejian Zou; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2022-10-12       Impact factor: 22.096

5.  Identification of biomarkers related to neutrophils and two molecular subtypes of systemic lupus erythematosus.

Authors:  Huiyan Li; Pingting Yang
Journal:  BMC Med Genomics       Date:  2022-07-20       Impact factor: 3.622

6.  Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis.

Authors:  Corinna Preuße; Barbara Paesler; Christopher Nelke; Derya Cengiz; Thomas Müntefering; Andreas Roos; Damien Amelin; Yves Allenbach; Akinori Uruha; Carsten Dittmayer; Andreas Hentschel; Marc Pawlitzki; Sarah Hoffmann; Sara Timm; Sarah Leonard Louis; Nora F Dengler; Heinz Wiendl; Jan D Lünemann; Albert Sickmann; Baptiste Hervier; Sven G Meuth; Udo Schneider; Anne Schänzer; Sabine Krause; Stylianos Tomaras; Eugen Feist; Rebecca Hasseli; Hans-Hilmar Goebel; Laure Gallay; Nathalie Streichenberger; Olivier Benveniste; Werner Stenzel; Tobias Ruck
Journal:  Acta Neuropathol       Date:  2022-05-25       Impact factor: 15.887

7.  Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis.

Authors:  Mariele Gatto; Annika Wiedemann; Nadja Nomovi; Karin Reiter; Eva Schrezenmeier; Thomas Rose; Franziska Szelinski; Andreia C Lino; Sonia Valentino; Anna Ghirardello; Thomas Dörner; Andrea Doria
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

8.  Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus.

Authors:  Kaili Liang; Jing He; Yunbo Wei; Qunxiong Zeng; Dongcheng Gong; Jiahuan Qin; Huihua Ding; Zhian Chen; Ping Zhou; Peng Niu; Qian Chen; Chenguang Ding; Liangjing Lu; Xiao-Xiang Chen; Zhanguo Li; Nan Shen; Di Yu; Jun Deng
Journal:  Clin Transl Immunology       Date:  2021-06-01

9.  S100A9 Derived From Myeloma Associated Myeloid Cells Promotes TNFSF13B/TNFRSF13B-Dependent Proliferation and Survival of Myeloma Cells.

Authors:  Lingzhang Meng; Qiang Tang; Jingjie Zhao; Zechen Wang; Liuzhi Wei; Qiuju Wei; Lianfei Yin; Shiguan Luo; Jian Song
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

10.  IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis.

Authors:  Kongyang Ma; Wenhan Du; Fan Xiao; Man Han; Enyu Huang; Na Peng; Yuan Tang; Chong Deng; Lixiong Liu; Yulan Chen; Jingjing Li; Shiwen Yuan; Qin Huang; Xiaoping Hong; Dajun Hu; Xiaoyan Cai; Quan Jiang; Dongzhou Liu; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2020-09-11       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.